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to be weaned off hemodialysis along with 
the benefit of concurrent amelioration of 
renovascular hypertension. 
Conclusion: For select patients with 
RAO there can benefits, such as achieving 
dialysis independence and stabilization of 
renovascular hypertension, by attaining 
revascularization of the renal arteries despite 
prolonged time of ischemia. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.041
No Survival Advantage Exists for Patients Undergoing Loop Ileostomy for Clostridium difficile Colitis
Bradley R. Hall, Andrew Cannon, Pranita Atri, Christopher S. Wichman, Lynette M. Smith, Apar K. 
Ganti, Chandrakanth Are, Aaron R. Sasson, Sushil Kumar, Surinder K. Batra
Mentor: Dmitry Oleynikov
Program: General Surgery 
Background & Objectives: Loop ileostomy 
(LI) remains an unproved alternative to total
abdominal colectomy (TAC) for patients
with Clostridium difficile infection (CDI).
We aim to compare outcomes between loop
ileostomy and total abdominal colectomy for
Clostridium difficile infection using a national
database.
Methods: The 2011-2016 ACS-NSQIP 
database was queried for patients who 
underwent LI or TAC for CDI. Patients with 
high outlying age, LOS, and operative time 
were excluded. Statistics were performed 
using IBM SPSS and NCSS PASS 11.
Results: Of 457 patients identified, 47 
underwent LI. Predicted morbidity was higher 
in the TAC cohort (62% vs. 37%, p<0.001). 
Patients in the LI cohort experienced fewer 
complications (72% vs. 87%, p=0.021); 
however, mortality did not differ between 
LI (36%) and TAC (31%) cohorts. Blood 
transfusions were more than twice as 
frequent in the TAC cohort (54% vs. 19%, 
p<0.001). Four patients in the LI cohort 
required reoperation; however, none required 
colectomy. 
Conclusions: Compared to TAC, LI does not 
improve survival for patients who require 
surgical intervention for CDI. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.042
Advanced Pancreatic Cancer: A Meta-Analysis of Clinical Trials over Thirty Years
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Background & Objectives: In contrast to 
other cancers, survival rates for pancreatic 
ductal adenocarcinoma (PDAC) have 
improved but minimally over the past thirty 
years. The aim of this study was to perform a 
meta-analysis of clinical trials published since 
1986 to determine trends in median overall 
survival in primarily metastatic PDAC.
Methods: All Phase 2-4 clinical trials 
published during or after 1986 investigating 
first-line systemic chemotherapy in metastatic 
PDAC were included in the meta-analysis. 
Publications obtained through PubMed and 
www.ClinicalTrials.gov were cross-referenced 
to identify additional trials. Trials enrolling 
fewer than 50% of study participants with 
metastatic disease were excluded. 
Results: Of 19,488 patients enrolled in 151 
clinical trials, 84% had metastatic disease 
and 16% had locally advanced pancreatic 
cancer. In clinical trials published from 1986 
to 2016, the weighted median overall survival 
(wMOS) increased by 3.0 months. The 
median wMOS was higher in combination 
therapy (7.31 months, IQR 5.4 to 8.5) 
compared to non-gemcitabine, single-agent 
therapy (4.76 months, IQR 3.5 to 6.0), 
gemcitabine monotherapy (6.48 months, IQR 
5.9 to 7.2), and gemcitabine plus single-agent 
therapy (7.09 months, IQR 6.3 to 8.2). Of all 
regimens used in more than one study arm, 
FOLFIRINOX had the highest wMOS (10.9 
months). 
Conclusions: Regardless of treatment 
regimen, survival rates in PDAC have 
minimally improved over time. Of drugs 
used in two or more study arms, only 
FOLFIRINOX has a wMOS greater than ten 
months. Emphasis should, therefore, be placed 
on identification of novel targets that promote 
early diagnosis and intervention. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.043
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Background: The management and prognosis 
of pancreatic adenocarcinoma varies 
depending on the location of the primary 
lesion within the pancreas. There is a paucity 
of data on survival trends in pancreatic 
adenocarcinoma based on the location. The 
49 
aim of this study was to analyze the national 
trends in survival for patients with pancreatic 
adenocarcinoma based on the location of the 
primary lesion. 
Methods: The Surveillance, Epidemiology, 
and End Results (SEER) database (SEER 17, 
1973-2007) was used to identify patients with 
pancreatic cancer located in the head (C25.0), 
body (C25.1), or tail (C25.2). SEER*Stat 
6.6.2 was used to calculate 5-year survival 
data. To stabilize rates, we used 5-year cohorts 
when calculating trends. 
Results: A total of 89,733 patients were 
included in the study. The overall 5-year 
survival, inclusive of all locations and 
treatment approaches was is 5.4% (95% CI 
5.2-5.6%). For lesions in the head, body and 
tail the overall 5-year survival, inclusive of 
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